Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

This study looks at whether giving immunotherapy (a drug that activates the immune system) at a specific time during the day — morning vs. evening — affects how well it works against resectable (surgically removable) non-small cell lung cancer when given before surgery alongside chemotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed stage II or III non-small cell lung cancer that can be surgically removed - You have not yet received any treatment for your current lung cancer - You have been assessed by a multidisciplinary team as suitable for neoadjuvant (pre-surgery) immunotherapy and chemotherapy - Your general health (ECOG 0–1) and organ function meet study requirements **You may NOT be eligible if...** - Your tumor has EGFR mutations or ALK/ROS1 gene rearrangements (you would be directed to targeted therapy) - You have active brain metastases - You have had another cancer within the past 3 years - You have active autoimmune disease or are on immunosuppressants - You have active hepatitis B, C, or HIV - You are pregnant or breastfeeding - You have a known severe allergy to PD-1 or PD-L1 inhibitors Talk to your doctor to see if this trial is right for you.